The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

Shares of biotech Intellia Therapeutics ( NTLA 5.18%) are down by around 33% over the past 30 days, amid the publication of ...

Ultromics' EchoGo® Amyloidosis, clinical AI for echocardiography with the potential to revolutionize early detection of ...

Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software that helps with the early diagnosis of cardiac amyloidosis, enabling timely ...

Alnylam Pharmaceuticals ALNY presented new data from its early-stage study of nucresiran (formerly ALN-TTRsc04) for treating ...

According to Alnylam’s Tim Mooney, mivelsiran’s endurance is due to stabilizing tweaks the scientists made to the siRNA ...

Alnylam Pharmaceuticals has revealed new interim data from its Phase I trial of nucresiran, a ribonucleic acid interference ...

A new type of therapy that "edits" a gene in patients with a rare heart condition has been shown to be safe and effective, ...

Results for the Phase I clinical trial, published in the New England Journal of Medicine, bring hope for people with transthyretin amyloidosis (ATTR), who have a build-up of misfolded transthyretin ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...